Net result improved significantly year-over-year, driven by lower write-downs and divestments in listed holdings. Portfolio remains diversified, with increased optimism in the local innovation market and a notable exit in Saga Diagnostics expected to yield a substantial gain.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.